Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jessica Ravikoff Allegretti, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. R01DK126448 (SNAPPER, SCOTT B) Sep 1, 2020 - Jun 30, 2025
    NIH
    Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of Crohn’s Disease
    Role: Co-Principal Investigator
  2. K23DK120898 (ALLEGRETTI, JESSICA R.) May 1, 2020 - Jan 31, 2025
    NIH
    Understanding Clostridium difficile Infection in Patients with inflammatory Bowel Disease
    Role: Principal Investigator
  3. R21DK118951 (SNAPPER, SCOTT B) Aug 21, 2018 - Jul 31, 2021
    NIH
    Low dose interleukin 2 for the expansion of regulatory T cells and the treatment of moderate to severe ulcerative colitis
    Role: Co-Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Chang LL, Allegretti J, Skinner AM, Dubberke ER. Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection. N Engl J Med. 2023 Feb 16; 388(7):654-656. PMID: 36791167.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  2. Lee SD, Allegretti JR, Steinwurz F, Connelly SB, Lawendy N, Paulissen J, Gecse KB. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore. BMC Gastroenterol. 2023 Feb 08; 23(1):34. PMID: 36755231; PMCID: PMC9906955.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  3. Feuerstadt P, Allegretti JR, Khanna S. Practical Use of Rebyota for the Prevention of Recurrent Clostridioides difficile Infection. Am J Gastroenterol. 2023 Jan 25. PMID: 36695753.
    Citations:    Fields:    
  4. Mullish BH, Martinez-Gili L, Allegretti JR. Editorial: the acid test-can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply. Aliment Pharmacol Ther. 2023 01; 57(1):169-170. PMID: 36480711.
    Citations:    Fields:    Translation:Humans
  5. Bustamante JM, Dawson T, Loeffler C, Marfori Z, Marchesi JR, Mullish BH, Thompson CC, Crandall KA, Rahnavard A, Allegretti JR, Cummings BP. Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans. Nutrients. 2022 Dec 07; 14(24). PMID: 36558359; PMCID: PMC9785599.
    Citations:    Fields:    Translation:HumansCells
  6. Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program. Patient. 2023 03; 16(2):95-103. PMID: 36336750; PMCID: PMC9911479.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  7. Dalal RS, Bains K, Marcus J, McClure EL, Allegretti JR. Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series. Inflamm Bowel Dis. 2022 11 02; 28(11):1787-1789. PMID: 35792486.
    Citations: 1     Fields:    Translation:Humans
  8. Mullish BH, Martinez-Gili L, Chekmeneva E, Correia GDS, Lewis MR, Horneffer-Van Der Sluis V, Roberts LA, McDonald JAK, Pechlivanis A, Walters JRF, McClure EL, Marchesi JR, Allegretti JR. Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection. Aliment Pharmacol Ther. 2022 12; 56(11-12):1556-1569. PMID: 36250604.
    Citations:    Fields:    Translation:HumansCells
  9. Allegretti JR. Should faecal microbiota transplantation be used earlier in the treatment framework? Lancet Gastroenterol Hepatol. 2022 12; 7(12):1062-1063. PMID: 36152634.
    Citations: 1     Fields:    Translation:HumansCells
  10. Vaughn BP, Fischer M, Kelly CR, Allegretti JR, Graiziger C, Thomas J, McClure E, Kabage AJ, Khoruts A. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2022 Sep 17. PMID: 36126907.
    Citations: 2     Fields:    
  11. Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, Hasson BR, Fonte AT, McChalicher C, Ege DS, Bryant JA, Straub TJ, Ford CB, Henn MR, Wang EEL, von Moltke L, Wilcox MH. SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI). Antibiotics (Basel). 2022 Sep 10; 11(9). PMID: 36140013; PMCID: PMC9495252.
    Citations: 2     
  12. Dalal RS, Mitri J, Goodrick H, Allegretti JR. Risk of Gastrointestinal Infections After Initiating Vedolizumab and Anti-TNFa Agents for Ulcerative Colitis. J Clin Gastroenterol. 2022 Aug 04. PMID: 36156528; PMCID: PMC9898464.
    Citations:    Fields:    
  13. Dalal RS, Pruce JC, Allegretti JR. Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2022 Jul 30. PMID: 35907202.
    Citations: 1     Fields:    
  14. Shore BM, Weaver KN, Allegretti JR, Herfarth HH, Barnes EL. Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn's-like Disease of the Pouch. Inflamm Bowel Dis. 2022 Jul 29. PMID: 35905034.
    Citations:    Fields:    
  15. Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-Brandt J, Cappelleri JC, Guo X, Khan N. Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol. 2022 Jul 26; 22(1):356. PMID: 35883049; PMCID: PMC9327372.
    Citations: 1     Fields:    
  16. Dawkins JJ, Allegretti JR, Gibson TE, McClure E, Delaney M, Bry L, Gerber GK. Gut metabolites predict Clostridioides difficile recurrence. Microbiome. 2022 06 09; 10(1):87. PMID: 35681218; PMCID: PMC9178838.
    Citations: 2     Fields:    Translation:HumansCells
  17. Gupta S, Allegretti JR. Mimics of Crohn's Disease. Gastroenterol Clin North Am. 2022 06; 51(2):241-269. PMID: 35595413.
    Citations:    Fields:    Translation:Humans
  18. Dalal RS, McClure EL, Marcus J, Allegretti JR. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis. Dig Dis Sci. 2023 01; 68(1):223-232. PMID: 35415826.
    Citations:    Fields:    Translation:Humans
  19. Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-Brandt J, Cappelleri JC, Guo X, Khan N. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol. 2022 Apr 09; 22(1):177. PMID: 35397501; PMCID: PMC8994921.
    Citations: 1     Fields:    Translation:Humans
  20. Osman M, Budree S, Kelly CR, Panchal P, Allegretti JR, Kassam Z. Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study. Gastroenterology. 2022 07; 163(1):319-322. PMID: 35398345.
    Citations: 3     Fields:    Translation:HumansCells
  21. Hassan-Zahraee M, Ye Z, Xi L, Baniecki ML, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J, Ziemek D, Neelakantan S, Lepsy C, Allegretti JR, Romatowski J, Scherl EJ, Klopocka M, Danese S, Chandra DE, Schoenbeck U, Vincent MS, Longman R, Hung KE. Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. Inflamm Bowel Dis. 2022 03 02; 28(3):434-446. PMID: 34427649; PMCID: PMC8889296.
    Citations: 4     Fields:    Translation:Humans
  22. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman N. Response to McFarland et al. Am J Gastroenterol. 2022 03 01; 117(3):501-502. PMID: 35137698.
    Citations: 1     Fields:    Translation:HumansCells
  23. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. Correction to: ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2022 02 01; 117(2):358. PMID: 34658366.
    Citations:    Fields:    
  24. Dalal RS, Gupta S, Goodrick H, Mitri J, Allegretti JR. Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. Inflamm Bowel Dis. 2022 01 05; 28(1):146-149. PMID: 34245267; PMCID: PMC8730681.
    Citations: 3     Fields:    Translation:Humans
  25. Dalal R, Mitri J, Goodrick H, Allegretti J. P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis. Am J Gastroenterol. 2021 Dec 01; 116(Suppl 1):S19. PMID: 35006199.
    Citations:    Fields:    
  26. Allegretti JR, Canakis A, McClure E, Marcus J, Norton BA, Hamilton MJ, Winter RW, De Silva PS, Friedman S, Korzenik JR. Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated. Inflamm Bowel Dis. 2021 11 15; 27(12):2031-2033. PMID: 34142700.
    Citations:    Fields:    Translation:Humans
  27. Montano-Loza AJ, Allegretti JR, Cheung A, Ebadi M, Jones D, Kerkar N, Levy C, Rizvi S, Vierling JM, Alvarez F, Bai W, Gilmour S, Gulamhusein A, Guttman O, Hansen BE, MacParland S, Mason A, Onofrio F, Santamaria P, Stueck A, Swain M, Vincent C, Ricciuto A, Hirschfield G. Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. Can Liver J. 2021; 4(4):401-425. PMID: 35989897; PMCID: PMC9235119.
    Citations:    
  28. Dalal RS, Allegretti JR. Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause? Inflamm Bowel Dis. 2021 10 20; 27(11):1873-1875. PMID: 33501941; PMCID: PMC8528143.
    Citations:    Fields:    Translation:Humans
  29. Dalal RS, Mitri J, Goodrick H, Allegretti JR. Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis. Inflamm Bowel Dis. 2021 10 18; 27(10):1694-1697. PMID: 33988235; PMCID: PMC8522788.
    Citations: 2     Fields:    Translation:Humans
  30. Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Hurtado J, Carrellas M, Marcus J, Marchesi JR, McDonald JAK, Gerardin Y, Silverstein M, Pechlivanis A, Barker GF, Miguens Blanco J, Alexander JL, Gallagher KI, Pettee W, Phelps E, Nemes S, Sagi SV, Bohm M, Kassam Z, Fischer M. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Inflamm Bowel Dis. 2021 08 19; 27(9):1371-1378. PMID: 33155639; PMCID: PMC8376126.
    Citations: 15     Fields:    Translation:HumansCells
  31. Dalal RS, Njie C, Marcus J, Gupta S, Allegretti JR. Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification. Inflamm Bowel Dis. 2021 07 27; 27(8):1294-1301. PMID: 33146703; PMCID: PMC8314105.
    Citations: 13     Fields:    Translation:Humans
  32. Dalal RS, Allegretti JR. Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease. Curr Opin Gastroenterol. 2021 07 01; 37(4):336-343. PMID: 33654015; PMCID: PMC8169557.
    Citations: 2     Fields:    Translation:HumansCells
  33. Gerardin Y, Timberlake S, Allegretti JR, Smith MB, Kassam Z. Beyond Fecal Microbiota Transplantation: Developing Drugs from the Microbiome. J Infect Dis. 2021 06 16; 223(12 Suppl 2):S276-S282. PMID: 33330910.
    Citations: 5     Fields:    Translation:HumansCells
  34. Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol. 2021 11; 19(11):2324-2332.e6. PMID: 34126262.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  35. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021 06 01; 116(6):1124-1147. PMID: 34003176.
    Citations: 50     Fields:    Translation:HumansCells
  36. Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol. 2021; 14:17562848211017725. PMID: 34104212.
    Citations: 14     
  37. Dalal RS, Allegretti JR. Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All. Inflamm Bowel Dis. 2021 05 17; 27(6):e70. PMID: 33570151; PMCID: PMC8128381.
    Citations: 1     Fields:    Translation:Humans
  38. Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol. 2021 04; 116(4):647-656. PMID: 33982930.
    Citations: 13     Fields:    Translation:HumansCells
  39. Allegretti JR, Nije C, McClure E, Redd WD, Wong D, Zhou JC, Bazarbashi AN, McCarty TR, Hathorn KE, Shen L, Jajoo K, Chan WW. Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019. JGH Open. 2021 May; 5(5):622-625. PMID: 34013064.
    Citations: 12     
  40. Dalal RS, Esckilsen S, Barnes EL, Pruce JC, Marcus J, Allegretti JR. Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2022 Oct; 20(10):2399-2401.e4. PMID: 33775893; PMCID: PMC8464615.
    Citations: 7     Fields:    Translation:Humans
  41. Gupta S, Zhu J, McCarty TR, Pruce J, Kassam Z, Kelly C, Fischer M, Allegretti JR. Cost-effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection. J Gastroenterol Hepatol. 2021 Sep; 36(9):2432-2440. PMID: 33682170.
    Citations: 1     Fields:    Translation:HumansCells
  42. Winter RW, Ananthakrishnan A, Burke KE, Kochar B, Chan WW, Allegretti JR. Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 03 15; 27(4):590-592. PMID: 33570095; PMCID: PMC7928903.
    Citations:    Fields:    Translation:Humans
  43. Fujimoto K, Kimura Y, Allegretti JR, Yamamoto M, Zhang YZ, Katayama K, Tremmel G, Kawaguchi Y, Shimohigoshi M, Hayashi T, Uematsu M, Yamaguchi K, Furukawa Y, Akiyama Y, Yamaguchi R, Crowe SE, Ernst PB, Miyano S, Kiyono H, Imoto S, Uematsu S. Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation. Gastroenterology. 2021 05; 160(6):2089-2102.e12. PMID: 33577875; PMCID: PMC8684800.
    Citations: 18     Fields:    Translation:HumansCells
  44. Ianiro G, Mullish BH, Hvas CL, Segal JP, Kuijper EJ, Costello SP, Kelly CR, Allegretti JR, Fischer M, Iqbal TH, Satokari R, Kao D, van Prehn J, Ng SC, Bibbò S, Baunwall SMD, Quraishi MN, Sokol H, Zhang F, Keller J, Masucci L, Quaranta G, Kassam Z, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota G. SARS-CoV-2 vaccines and donor recruitment for FMT. Lancet Gastroenterol Hepatol. 2021 04; 6(4):264-266. PMID: 33571456; PMCID: PMC7906701.
    Citations: 2     Fields:    Translation:Humans
  45. Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol. 2021 Feb 05. PMID: 33606488.
    Citations:    Fields:    
  46. Dalal RS, McClure E, Marcus J, Winter RW, Hamilton MJ, Allegretti JR. COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 08; 19(8):1730-1732.e2. PMID: 33549869.
    Citations: 26     Fields:    Translation:HumansCellsPHPublic Health
  47. Burke KE, Kochar B, Allegretti JR, Winter RW, Lochhead P, Khalili H, Colizzo FP, Hamilton MJ, Chan WW, Ananthakrishnan AN. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 01 19; 27(2):155-161. PMID: 33089863; PMCID: PMC7665507.
    Citations: 35     Fields:    Translation:HumansCells
  48. Allegretti JR, Kassam Z, Hurtado J, Marchesi JR, Mullish BH, Chiang A, Thompson CC, Cummings BP. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. Hormones (Athens). 2021 Mar; 20(1):209-211. PMID: 33420959.
    Citations: 12     Fields:    Translation:Humans
  49. Allegretti JR. Update on Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2021 Jan; 17(1):31-34. PMID: 34035760.
    Citations:    
  50. Martinez-Gili L, McDonald JAK, Liu Z, Kao D, Allegretti JR, Monaghan TM, Barker GF, Miguéns Blanco J, Williams HRT, Holmes E, Thursz MR, Marchesi JR, Mullish BH. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites. Gut Microbes. 2020 11 09; 12(1):1810531. PMID: 32893721.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  51. Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine L. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3. PMID: 33011173.
    Citations: 32     Fields:    Translation:HumansCells
  52. Gupta S, Aihara H, Trivedi HD, Srivastava A, Allegretti JR, Hamilton MJ. Heading in the Right Dissection: Toward an Endoscopic Cancer Cure in a Patient with Long-Standing Ulcerative Colitis. Dig Dis Sci. 2020 10; 65(10):2818-2822. PMID: 32661762.
    Citations:    Fields:    Translation:Humans
  53. Perler BK, Chen B, Phelps E, Allegretti JR, Fischer M, Ganapini V, Krajiceck E, Kumar V, Marcus J, Nativ L, Kelly CR. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection. J Clin Gastroenterol. 2020 09; 54(8):701-706. PMID: 32011405.
    Citations: 14     Fields:    Translation:HumansCells
  54. Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Kassam Z, Fischer M. Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection. Gastroenterology. 2020 11; 159(5):1982-1984. PMID: 32738249.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  55. Cheng YW, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, Ghabril M, Orman E, Sashidhar S, Rogers N, Xu H, Khoruts A, Vaughn B, Kao D, Wong K, Cammarota G, Ianiro G, Dhere T, Kraft CS, Mehta N, Woodworth MH, Allegretti JR, Nativ L, Marcus J, El-Nachef N, Fischer M. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1627-1634. PMID: 32645451; PMCID: PMC8856132.
    Citations: 11     Fields:    Translation:HumansCells
  56. Proença IM, Allegretti JR, Bernardo WM, de Moura DTH, Ponte Neto AM, Matsubayashi CO, Flor MM, Kotinda APST, de Moura EGH. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. Nutr Res. 2020 11; 83:1-14. PMID: 32987284.
    Citations: 14     Fields:    Translation:Humans
  57. Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, Iqbal TH, Allegretti JR, Bibbò S, Sokol H, Zhang F, Fischer M, Costello SP, Keller JJ, Masucci L, van Prehn J, Quaranta G, Quraishi MN, Segal J, Kao D, Satokari R, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota G. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut. 2020 09; 69(9):1555-1563. PMID: 32620549; PMCID: PMC7456726.
    Citations: 49     Fields:    Translation:HumansCellsPHPublic Health
  58. Allegretti JR, Elliott RJ, Ladha A, Njenga M, Warren K, O'Brien K, Budree S, Osman M, Fischer M, Kelly CR, Kassam Z. Stool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation. Gut Microbes. 2020 11 01; 11(6):1806-1808. PMID: 32552337.
    Citations: 3     Fields:    Translation:HumansCells
  59. Ianiro G, Mullish BH, Kelly CR, Sokol H, Kassam Z, Ng SC, Fischer M, Allegretti JR, Masucci L, Zhang F, Keller J, Sanguinetti M, Costello SP, Tilg H, Gasbarrini A, Cammarota G. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020 05; 5(5):430-432. PMID: 32192627.
    Citations: 66     Fields:    Translation:HumansCellsPHPublic Health
  60. Allegretti JR, Mehta SR, Kassam Z, Kelly CR, Kao D, Xu H, Fischer M. Risk Factors that Predict the Failure of Multiple Fecal Microbiota Transplantations for Clostridioides difficile Infection. Dig Dis Sci. 2021 01; 66(1):213-217. PMID: 32170474.
    Citations: 3     Fields:    Translation:Humans
  61. Lopetuso LR, Ianiro G, Allegretti JR, Bibbò S, Gasbarrini A, Scaldaferri F, Cammarota G. Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opin Biol Ther. 2020 04; 20(4):343-351. PMID: 32083498.
    Citations: 17     Fields:    Translation:Humans
  62. Allegretti JR, Mullish BH. Faecal microbiota transplantations and urinary tract infections - Authors' reply. Lancet. 2020 01 25; 395(10220):271. PMID: 31982069.
    Citations: 1     Fields:    Translation:Humans
  63. Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020 04; 158(5):1465-1496.e17. PMID: 31945351; PMCID: PMC7117094.
    Citations: 28     Fields:    Translation:Humans
  64. Cheng YW, Phelps E, Nemes S, Rogers N, Sagi S, Bohm M, El-Halabi M, Allegretti JR, Kassam Z, Xu H, Fischer M. Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2020 09; 18(10):2234-2243.e1. PMID: 31923639.
    Citations: 18     Fields:    Translation:HumansCells
  65. Kassam Z, Dubois N, Ramakrishna B, Ling K, Qazi T, Smith M, Kelly CR, Fischer M, Allegretti JR, Budree S, Panchal P, Kelly CP, Osman M. Donor Screening for Fecal Microbiota Transplantation. N Engl J Med. 2019 11 21; 381(21):2070-2072. PMID: 31665572.
    Citations: 40     Fields:    Translation:Humans
  66. Allegretti JR, Marcus J, Storm M, Sitko J, Kennedy K, Gerber GK, Bry L. Clinical Predictors of Recurrence After Primary Clostridioides difficile Infection: A Prospective Cohort Study. Dig Dis Sci. 2020 06; 65(6):1761-1766. PMID: 31667694; PMCID: PMC8630805.
    Citations: 3     Fields:    Translation:HumansCells
  67. Elangovan A, Allegretti JR, Fischer M. Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. Expert Opin Biol Ther. 2019 12; 19(12):1343-1355. PMID: 31570017.
    Citations: 3     Fields:    Translation:HumansAnimals
  68. Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WW. Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019 10; 53(9):e405-e408. PMID: 30882536.
    Citations: 7     Fields:    Translation:HumansCells
  69. Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP, Sokol H, Kump P, Satokari R, Kahn SA, Kao D, Arkkila P, Kuijper EJ, Vehreschild MJG, Pintus C, Lopetuso L, Masucci L, Scaldaferri F, Terveer EM, Nieuwdorp M, López-Sanromán A, Kupcinskas J, Hart A, Tilg H, Gasbarrini A. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019 12; 68(12):2111-2121. PMID: 31563878; PMCID: PMC6872442.
    Citations: 121     Fields:    Translation:HumansCells
  70. Allegretti JR, Mullish BH, Kelly C, Fischer M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet. 2019 08 03; 394(10196):420-431. PMID: 31379333.
    Citations: 100     Fields:    Translation:Humans
  71. Allegretti JR, Kassam Z. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: The Next Steps in This Promising Story. Am J Gastroenterol. 2019 08; 114(8):1354-1355. PMID: 31306151.
    Citations: 2     Fields:    Translation:Humans
  72. Allegretti JR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, Marchesi JR, McDonald JAK, Pechlivanis A, Barker GF, Miguéns Blanco J, Garcia-Perez I, Wong WF, Gerardin Y, Silverstein M, Kennedy K, Thompson C. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol. 2020 04; 18(4):855-863.e2. PMID: 31301451.
    Citations: 81     Fields:    Translation:HumansAnimals
  73. Allegretti JR, Kassam Z, Carrellas M, Mullish BH, Marchesi JR, Pechlivanis A, Smith M, Gerardin Y, Timberlake S, Pratt DS, Korzenik JR. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Am J Gastroenterol. 2019 07; 114(7):1071-1079. PMID: 30730351.
    Citations: 59     Fields:    Translation:HumansCTClinical Trials
  74. Allegretti JR, Fischer M, Sagi SV, Bohm ME, Fadda HM, Ranmal SR, Budree S, Basit AW, Glettig DL, de la Serna EL, Gentile A, Gerardin Y, Timberlake S, Sadovsky R, Smith M, Kassam Z. Correction to: Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Low Dose. Dig Dis Sci. 2019 Jul; 64(7):2059. PMID: 30778870.
    Citations: 1     Fields:    
  75. Kelly CR, Fischer M, Grinspan A, Allegretti JR. Patients Eligible for Trials of Microbe-Based Therapeutics Do Not Represent the Population With Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2020 05; 18(5):1099-1101. PMID: 31254675.
    Citations: 5     Fields:    Translation:HumansCells
  76. McSweeney B, Allegretti JR, Fischer M, Xu H, Goodman KJ, Monaghan T, McLeod C, Mullish BH, Petrof EO, Phelps EL, Chis R, Edmison A, Juby A, Ennis-Davis R, Roach B, Wong K, Kao D. In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation. Gut Microbes. 2020; 11(1):51-62. PMID: 31122134.
    Citations: 11     Fields:    Translation:Humans
  77. Hathorn K, Qazi T, Caton MT, Allegretti JR. Cryptogenic Multifocal Ulcerative Sclerosing Enteritis: A Curious Case of Intestinal Obstruction in the Setting of Human Immunodeficiency Virus. ACG Case Rep J. 2019 May; 6(5):e00070. PMID: 31616747; PMCID: PMC6658071.
    Citations:    
  78. Levy AN, Allegretti JR. Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease. Therap Adv Gastroenterol. 2019; 12:1756284819836893. PMID: 30906424; PMCID: PMC6421596.
    Citations: 31     
  79. Mullish BH, McDonald JAK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGM, Glegola-Madejska I, Williams HRT, Holmes E, Clarke TB, Thursz MR, Marchesi JR. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut. 2019 10; 68(10):1791-1800. PMID: 30816855; PMCID: PMC6839797.
    Citations: 85     Fields:    Translation:HumansAnimalsCells
  80. Santiago M, Eysenbach L, Allegretti J, Aroniadis O, Brandt LJ, Fischer M, Grinspan A, Kelly C, Morrow C, Rodriguez M, Osman M, Kassam Z, Smith MB, Timberlake S. Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent C. difficile infections in a multi-center retrospective study. AIMS Microbiol. 2019; 5(1):1-18. PMID: 31384699; PMCID: PMC6646931.
    Citations: 5     
  81. Allegretti JR, Kao D, Phelps E, Roach B, Smith J, Ganapini VC, Kassam Z, Xu H, Fischer M. Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis? Dig Dis Sci. 2019 06; 64(6):1668-1671. PMID: 30632052.
    Citations: 12     Fields:    Translation:Humans
  82. Allegretti JR, Fischer M, Sagi SV, Bohm ME, Fadda HM, Ranmal SR, Budree S, Basit AW, Glettig DL, de la Serna EL, Gentile A, Gerardin Y, Timberlake S, Sadovsky R, Smith M, Kassam Z. Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose. Dig Dis Sci. 2019 06; 64(6):1672-1678. PMID: 30519847.
    Citations: 22     Fields:    Translation:Humans
  83. Merker AM, Riaz M, Friedman S, Allegretti JR, Korzenik J. Legalization of Medicinal Marijuana Has Minimal Impact on Use Patterns in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2309-2314. PMID: 29788102.
    Citations: 7     Fields:    Translation:Humans
  84. Krajicek E, Fischer M, Allegretti JR, Kelly CR. Nuts and Bolts of Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol. 2019 01; 17(2):345-352. PMID: 30268564.
    Citations: 15     Fields:    Translation:HumansPHPublic Health
  85. Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH, Dhere T, Kraft CS, Kao D, Smith J, Le L, El-Nachef N, Kaur N, Kowsika S, Ehrlich A, Smith M, Safdar N, Misch EA, Allegretti JR, Flynn A, Kassam Z, Sharfuddin A, Vuppalanchi R, Fischer M. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant. 2019 02; 19(2):501-511. PMID: 30085388; PMCID: PMC6349556.
    Citations: 35     Fields:    Translation:HumansCells
  86. Kearney SM, Gibbons SM, Poyet M, Gurry T, Bullock K, Allegretti JR, Clish CB, Alm EJ. Endospores and other lysis-resistant bacteria comprise a widely shared core community within the human microbiota. ISME J. 2018 10; 12(10):2403-2416. PMID: 29899513.
    Citations: 15     Fields:    Translation:HumansCells
  87. Panchal P, Budree S, Scheeler A, Medina G, Seng M, Wong WF, Elliott R, Mitchell T, Kassam Z, Allegretti JR, Osman M. Correction to: Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Curr Gastroenterol Rep. 2018 06 08; 20(7):28. PMID: 29884929.
    Citations: 1     Fields:    
  88. Panchal P, Budree S, Scheeler A, Medina G, Seng M, Wong WF, Eliott R, Mitchell T, Kassam Z, Allegretti JR, Osman M. Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. Curr Gastroenterol Rep. 2018 03 28; 20(4):14. PMID: 29594746.
    Citations: 14     Fields:    Translation:Humans
  89. Smillie CS, Sauk J, Gevers D, Friedman J, Sung J, Youngster I, Hohmann EL, Staley C, Khoruts A, Sadowsky MJ, Allegretti JR, Smith MB, Xavier RJ, Alm EJ. Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. Cell Host Microbe. 2018 Feb 14; 23(2):229-240.e5. PMID: 29447696.
    Citations: 133     Fields:    Translation:HumansCellsPHPublic Health
  90. Allegretti JR, Kao D, Sitko J, Fischer M, Kassam Z. Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure. Clin Infect Dis. 2018 01 06; 66(1):134-135. PMID: 29020157.
    Citations: 15     Fields:    Translation:Humans
  91. Fischer M, Kao D, Kassam Z, Smith J, Louie T, Sipe B, Torbeck M, Xu H, Ouyang F, Mozaffarian D, Allegretti JR. Stool Donor Body Mass Index Does Not Affect Recipient Weight After a Single Fecal Microbiota Transplantation for Clostridium difficile Infection. Clin Gastroenterol Hepatol. 2018 08; 16(8):1351-1353. PMID: 29246701.
    Citations: 7     Fields:    Translation:Humans
  92. Allegretti JR, Kassam Z, Chan WW. Small Intestinal Bacterial Overgrowth: Should Screening Be Included in the Pre-fecal Microbiota Transplantation Evaluation? Dig Dis Sci. 2018 01; 63(1):193-197. PMID: 29188472; PMCID: PMC6139025.
    Citations: 3     Fields:    Translation:HumansCells
  93. Allegretti JR, Allegretti AS, Phelps E, Xu H, Fischer M, Kassam Z. Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures. Clin Gastroenterol Hepatol. 2018 11; 16(11):1832-1833. PMID: 29104129.
    Citations: 10     Fields:    Translation:HumansCells
  94. Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. Clin Microbiol Infect. 2018 Jul; 24(7):780.e1-780.e3. PMID: 29104169; PMCID: PMC6156785.
    Citations: 3     Fields:    Translation:HumansCells
  95. Allegretti J, Eysenbach LM, El-Nachef N, Fischer M, Kelly C, Kassam Z. The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present, and Future. Inflamm Bowel Dis. 2017 10; 23(10):1710-1717. PMID: 28858073.
    Citations: 22     Fields:    Translation:Humans
  96. Kelly CR, Allegretti JR. FMT in IBD: What Have We Learned? Dig Dis Sci. 2017 10; 62(10):2618-2620. PMID: 28840580.
    Citations: 1     Fields:    Translation:Humans
  97. Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes. 2017 11 02; 8(6):574-588. PMID: 28723262.
    Citations: 52     Fields:    Translation:Humans
  98. Razik R, Osman M, Lieberman A, Allegretti JR, Kassam Z. Faecal microbiota transplantation for Clostridium difficile infection: a multicentre study of non-responders. Med J Aust. 2017 08 21; 207(4):159-160. PMID: 28814217.
    Citations: 3     Fields:    Translation:HumansCells
  99. Allegretti JR, Kassam Z, Osman M, Budree S, Fischer M, Kelly CR. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc. 2018 01; 87(1):18-29. PMID: 28583769.
    Citations: 15     Fields:    Translation:HumansCells
  100. Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V, Korzenik J. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Dig Dis Sci. 2017 06; 62(6):1590-1596. PMID: 28357697; PMCID: PMC5661939.
    Citations: 19     Fields:    Translation:Humans
  101. Goettel J, Kotlarz D, Illig D, Canavan J, Allegretti J, Hamilton M, Kelly R, Griffith A, Carellas M, Nelina A, Bousvaros A, Korzenik J, Snapper S. O-011 Low-dose IL-2 Administration Expands Human Regulatory T Cells in Patients with UC and Humanized Mice and Protects Against Experimental Colitis. Inflamm Bowel Dis. 2017 Feb; 23 Suppl 1:S4. PMID: 28125559.
    Citations:    
  102. Barnes EL, Allegretti JR. Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2016 10; 50(9):733-41. PMID: 26535480.
    Citations: 9     Fields:    Translation:Humans
  103. Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, Rex D, Mellow M, Kaur N, Sokol H, Cook G, Hamilton MJ, Phelps E, Sipe B, Xu H, Allegretti JR. Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 10; 22(10):2402-9. PMID: 27580384.
    Citations: 72     Fields:    Translation:HumansCells
  104. Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, Gevers D, Ting A, Robson SC, Moss AC. Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. Inflamm Bowel Dis. 2016 09; 22(9):2182-90. PMID: 27542133; PMCID: PMC4995064.
    Citations: 89     Fields:    Translation:HumansCells
  105. Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JR. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016 06; 43(11):1142-53. PMID: 27086647; PMCID: PMC5214573.
    Citations: 70     Fields:    Translation:HumansCells
  106. Beltrami R, Chiesa M, Scribante A, Allegretti J, Poggio C. Comparison of shear bond strength of universal adhesives on etched and nonetched enamel. J Appl Biomater Funct Mater. 2016 Apr 06; 14(1):e78-83. PMID: 26952584.
    Citations: 20     Fields:    Translation:HumansAnimals
  107. Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis. 2015 Dec; 21(12):2879-85. PMID: 26288002; PMCID: PMC4745906.
    Citations: 65     Fields:    Translation:Humans
  108. Allegretti JR, Borges L, Lucci M, Chang M, Cao B, Collins E, Vogel B, Arthur E, Emmons D, Korzenik JR. Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Nov; 21(11):2583-9. PMID: 26244647; PMCID: PMC5189985.
    Citations: 25     Fields:    Translation:Humans
  109. Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 2015 May; 21(5):1089-97. PMID: 25895005; PMCID: PMC4458370.
    Citations: 35     Fields:    Translation:Humans
  110. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. 2014 Dec 08; (94). PMID: 25549239; PMCID: PMC4396937.
    Citations: 15     Fields:    Translation:HumansCells
  111. Allegretti JR, Hamilton MJ. Restoring the gut microbiome for the treatment of inflammatory bowel diseases. World J Gastroenterol. 2014 Apr 07; 20(13):3468-74. PMID: 24707129.
    Citations: 14     Fields:    Translation:HumansCells
  112. Ravikoff JE, Cole EB, Korzenik JR. Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives. Inflamm Bowel Dis. 2012 Nov; 18(11):2092-8. PMID: 22241674.
    Citations: 10     Fields:    Translation:Humans
  113. Badia A, Riano F, Ravikoff J, Khouri R, Gonzalez-Hernandez E, Orbay JL. Dynamic intradigital external fixation for proximal interphalangeal joint fracture dislocations. J Hand Surg Am. 2005 Jan; 30(1):154-60. PMID: 15680573.
    Citations: 15     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Allegretti's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (204)
Explore
_
Co-Authors (30)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.